Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US87807D1037
- Market cap
- 256K
- P/E ratio
- Not available
- Analyst target
- 48
- Dividend yield
- Not available
- Beta
- 0.01
About
About TC BioPharm Holdings PLC
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Visit company website
No comments yet
Start a focused discussion about TCBP.